Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children

Human Psychopharmacology

Volumn 24, Issue 7, 2009, Pages 584-589

  Mattai, Anand ^a   Fung, Lawrence ^a   Bakalar, Jennifer ^a   Overman, Gerald ^a   Tossell, Julia ^a   Miller, Rachel ^a   Rapoport, Judith ^a   Gogtay, Nitin ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Childhood onset schizophrenia; Clozapine; Lithium; Neutropenia

Indexed keywords

CLOZAPINE; LITHIUM CARBONATE;

ADJUVANT THERAPY; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; NEUTROPENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 72849112157     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1056     Document Type: Article

References (36)

1. Adityanjee. 1995. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry 152: 648-649.
2. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. 1993. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329: 162-167.
3. American Psychiatric Association. & American Psychiatric Association. Task Force on Dsm-IV. 2000. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association: Washington, DC.
4. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'sullivan D. 1996. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169: 483-488.
5. Bender S, Linka T, Wolstein J, et al. 2004. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol 7: 59-63.
6. Blier P, Slater S, Measham T, Koch M, Wiviott G. 1998. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 13: 137-140.
7. Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M. 2001. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry 13: 233-237.
8. Chengappa KN, Gopalani A, Haught MK, Mcchesney K, Baker RW, Schooler NR. 1996. The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Psychopharmacol Bull 32: 111-121. (Pubitemid 26176211)
9. Dunk LR, Annan LJ, Andrews CD. 2006. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188: 255-263.
10. Elkis H. 2007. Treatment-resistant schizophrenia. Psychiatr Clin North Am 30: 511-533.
11. Esposito D, Rouillon F, Limosin F. 2005. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 60: 759-764. (Pubitemid 40394568)
12. Essali A, Al-Haj Haasan N, Li C, Rathbone J. 2009. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 1: CD000059.
13. Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. 2005. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 44: 1024-1031. (Pubitemid 41377558)
14. Gogtay N, Rapoport J. 2008. Clozapine use in children and adolescents. Expert Opin Pharmacother 9: 459-465.
15. Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW. 1994. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 55: 429-432.
16. Kanaan RA, Kerwin RW. 2006. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 67: 756-760.
17. Kane JM. 1992. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry Suppl 17: 41-45.
18. Kranzler H, Roofeh D, Gerbino-Rosen G, et al. 2005. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44: 55-63. (Pubitemid 40019200)
19. Kranzler HN, Kester HM, Gerbino-Rosen G, et al. 2006. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am 15: 135-159. (Pubitemid 41735241)
20. Kumra S, Kranzler H, Gerbino-Rosen G, et al. 2008. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63: 524-529. (Pubitemid 351220784)
21. Lapierre G, Stewart RB. 1980. Lithium carbonate and leukocytosis. Am J Hosp Pharm 37: 1525-1528.
22. Lieberman JA. 1998. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 59 (Suppl 3): 38-43. (Pubitemid 28196369)
23. McEvoy JP, Lieberman JA, Stroup TS, et al. 2006. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600-610.
24. Munro J, O'sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. 1999. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 175: 576-580.
25. Nicolson R, Lenane M, Hamburger SD, Fernandez T, Bedwell J, Rapoport JL. 2000. Lessons from childhood-onset schizophrenia. Brain Res Brain Res Rev 31: 147-156.
26. Nicolson R, Rapoport JL. 1999. Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry 46: 1418-1428.
27. Ozdemir MA, Sofuoglu S, Tanrikulu G, Aldanmaz F, Esel E, Dundar S. 1994. Lithium-induced hematologic changes in patients with bipolar affective disorder. Biol Psychiatry 35: 210-213. (Pubitemid 24078488)
28. Phiel CJ, Klein PS. 2001. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789-813.
29. Porter R, Mohamed A. 2006. Diurnal variation of neutropenia during clozapine treatment. Int J Neuropsychopharmacol 9: 373-374. (Pubitemid 43780506)
30. Raison CL, Guze BH, Kissell RL. 1994. Successful treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. J Clin Psychopharmacol 14: 285-286. (Pubitemid 24254727)
31. Silverstone PH. 1998. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol 18: 86-88.
32. Small JG, Klapper MH, Malloy FW, Steadman TM. 2003. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 23: 223-228. (Pubitemid 36807788)
33. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. 2003. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 13: 401-404. (Pubitemid 37288536)
34. Sporn AL, Vermani A, Greenstein DK, et al. 2007. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46: 1349-1356. (Pubitemid 47462194)
35. Timmons BW, Tarnopolsky MA, Snider DP, Bar-Or O. 2006. Immunological changes in response to exercise: influence of age, puberty, and gender. Med Sci Sports Exerc 38: 293-304. (Pubitemid 43271581)
36. Usiskin SI, Nicolson R, Lenane M, Rapoport JL. 2000. Retreatment with clozapine after erythromycin-induced neutropenia. Am J Psychiatry 157: 1021.